Table 2.
Clinical performance of PSA glycoprofiling in serum samples as a prognostic PCa biomarker. HR, high-risk PCa patients; LR, low-risk PCa patients; IR, intermediate-risk PCa patients; Pbx GG, prostate biopsy grade group; GS, Gleason score; AAL, Aleuria aurantia lectin; PhoSL, Pholiota squarrosa lectin; for other abbreviations see table 1.
| no. | sample set 1 no. of samples |
sample set 2 no. of samples |
glycoprofiling | AUC | sens./specif. % | ref. |
|---|---|---|---|---|---|---|
| 12 | HR (22) | BPH + LR + IR (57) | no, PHI | 0.84 | 81.8/84.2 | [54] |
| 13 | HR (22) | BPH + LR + IR (57) | SNA, α-2,3-SA↑ | 0.97 | 81.8/96.5 | [54] |
| 14 | HR (22) | BPH + LR + IR (57) | PHI + SNA, α-2,3-SA↑ | 0.985 | 100/94.7 | [54] |
| 15 | HR (22) | BPH + LR + IR (51) | SNA, α-2,3-SA↑ | 0.97 | 85.7/95.5 | [65] |
| 16 | PCa, Pbx GG ≥ 3 (159) | PCa, Pbx GG ≤ 2 (85) | WFA, LacdiNAc↑ | 0.65 | 57.1/80.8 | [58] |
| 17 | PCa, GS > 6 (33) | PCa, GS = 6 (14) | AAL, α-1,6(3)-Fuc↑ | 0.71 | ND/ND | [66] |
| 18 | PCa, GS>8 (20) | PCa, GS = 6 (14) | AAL, α-1,6(3)-Fuc↑ | 0.86 | ND/ND | [66] |
| 19 | HR (22) | BPH + LR + IR (51) | PhoSL, core α-1,6-Fuc↓ | 0.94 | 90.0/95.0 | [65] |